LIXTE Biotechnology Holdings, Inc. LIXT shares are roaring higher Monday. The company announced preclinical results of LIXTE Biotechnology's collaboration with the Netherlands Cancer Institute.
What To Know:
LIXTE Biotechnology announced preclinical data that identified a novel mechanism in which LB-100 transforms "cold" tumors that are unresponsive to immune attacks into "hot" tumors that can be effectively targeted by the immune system. This newly discovered mechanism complements other mechanisms through which LB-100 enhances the sensitivity of cancer cells to immune checkpoint blockade, a type of immunotherapy.
John S. Kovach, M.D., CEO of LIXTE, stated, "This data further supports our focus on developing LB-100 in combination with checkpoint blockade antibodies and strengthens our expectation that our current and upcoming clinical trials combining LB-100 with immune checkpoint blockade will be effective in treating cancer."
Related News: Why Chewy Shares Are Moving Monday
LIXT Price Action: According to Benzinga Pro, LIXT shares have been halted multiple times and are trading 28% higher at $6.95 at the time of publication.
Image: PublicDomainPictures from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
